<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">ALLOPURINOL</span><br/>(al-oh-pure'i-nole)<br/><span class="topboxtradename">Alloprin A <img border="0" src="../images/maple.gif"/>, </span><span class="topboxtradename"> Alloprim, </span><span class="topboxtradename"> Apo-allopurinol-A <img border="0" src="../images/maple.gif"/>, </span><span class="topboxtradename">Lopurin, </span><span class="topboxtradename">Novopurinol A, </span><span class="topboxtradename"> Purinol <img border="0" src="../images/maple.gif"/>, </span><span class="topboxtradename">Zyloprim<br/></span><b>Classifications:</b> <span class="classification">antigout agent</span><br/><b>Pregnancy Category: </b>C<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>100 mg, 300 mg tablets; 500 mg vial</p>
<h1><a name="action">Actions</a></h1>
<p>Allopurinol reduces endogenous uric acid by selectively inhibiting action of xanthine oxidase, the enzyme responsible for
         converting hypoxanthine to xanthine and xanthine to uric acid (end product of purine catabolism). Has no analgesic, antiinflammatory,
         or uricosuric actions.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Thus, urate pool is decreased by the lowering of both serum and urinary uric acid levels, and hyperuricemia is prevented.</p>
<h1><a name="uses">Uses</a></h1>
<p>To control primary hyperuricemia that accompanies severe gout and to prevent possibility of flare-up of acute gouty attack;
         to prevent recurrent calcium oxalate stones; prophylactically to reduce severity of hyperuricemia associated with antineoplastic
         and radiation therapies, both of which greatly increase plasma uric acid levels by promoting nucleic acid degradation.
      </p>
<h1><a name="unlabeleduses">Unlabeled Uses</a></h1>
<p>To reduce hyperuricemia secondary to LeschNyhan syndrome, polycythemia vera, G6PD deficiency, sarcoidosis, and therapy
         with thiazides or ethambutol.
      </p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Hypersensitivity to allopurinol; as initial treatment for acute gouty attacks; idiopathic hemochromatosis (or those with family
         history); children (except those with hyperuricemia secondary to neoplastic disease and chemotherapy). Safety during pregnancy
         (category C) or lactation is not established.
      </p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>Impaired hepatic or renal function, history of peptic ulcer, lower GI tract disease, bone marrow depression.</p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Treatment Hyperuricemia</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 100 mg/d, may increase by 100 mg/wk (max: 800 mg/d), divide doses &gt;300 mg/d  <span class="rdroute">IV</span> 200400 mg/m<sup>2</sup>/d (max: 600 mg/d) in 14 divided doses<br/><span class="rdage">Child:</span> <span class="rdroute">PO</span> <img src="../images/special/lesserorequal.gif"/><i>10 y</i>, 10 mg/kg/d in 23 divided doses (max: 800 mg/d) <span class="rdroute">IV</span> 200 mg/m<sup>2</sup>/d in 14 divided doses<br/><br/><span class="indicationtitle">Treatment Secondary Hyperuricemia</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 200800 mg/d for 23 d or longer, divide doses &gt;300 mg/d<br/><span class="rdage">Child:</span> <span class="rdroute">PO</span>
<i>610 y</i>, 100 mg t.i.d., <i> 50 mg t.i.d.<br/><br/><span class="impairmenttitle">Renal Impairment (based on Cl<sub>Cr</sub> range)</span><br/>Cl<sub>cr</sub>: 80 mL/min = 250 mg/d; 60 mL/min = 200 mg/d; 40 mL/min = 150 mg/d; 20 mL/min = 100 mg/d; 10 mL/min = 100 mg q2d; 0 mL/min
               = 100 mg q3d; removed by hemodialysis.<br/><br/></i></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Oral</span><br/><ul>
<li>Give after meals for best toleration; tablet may be crushed and taken with fluid or mixed with food.</li>
<li>Store at 15°30° C (59°86° F) in a tightly closed container.</li>
</ul>
<table cellpadding="4" cellspacing="0" class="ivbox" width="100%">
<tr>
<td><span class="ivtitle">Intravenous</span><p><span class="routemethod">PREPARE:</span> <span class="methodtype"> Intermittent:</span>   Reconstitute a single dose vial (500 mg) with 25 mL of sterile water for injection to yield 20 mg/mL. Further dilute with NS or D5W to a concentration of <img src="../images/special/lesserorequal.gif"/>6 mg/mL. 
                  								Note: Adding 2.3 mL of diluent yields 6 mg/mL.
                  							 
               </p>
<p><span class="routemethod">ADMINISTER:</span> <span class="methodtype"> Intermittent:</span>  Usually administered over 3060 min.  
               </p>
<p><span class="routemethod">INCOMPATIBILITIES</span> <span class="incompattype"> Solution/Additive:</span>
<b>Amikacin,</b>
<b>amphotericin B,</b>
<b>carmustine,</b>
<b>cefotaxime,</b>
<b>chlorpromazine,</b>
<b>cimetidine,</b>
<b>clindamycin,</b>
<b>cytarabine,</b>
<b>dacarbazine,</b>
<b>daunorubicin,</b>
<b>doxycycline,</b>
<b>droperidol,</b>
<b>floxuridine,</b>
<b>gentamicin,</b>
<b>haloperidol,</b>
<b>hydroxyzine,</b>
<b>idarubicin,</b>
<b>imipenem-cilastatin,</b>
<b>mechlorethamine,</b>
<b>meperidine,</b>
<b>metoclopramide,</b>
<b> methylprednisolone,</b>
<b>minocycline,</b>
<b>nalbuphine,</b>
<b>netilmicin,</b>
<b>ondansetron,</b>
<b>prochlorperazine,</b>
<b>promethazine,</b>
<b>sodium bicarbonate,</b>
<b>streptozocin,</b>
<b>tobramycin,</b>
<b>vinorelbine.</b>
</p>
</td>
</tr>
</table>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">CNS:</span> Drowsiness, headache, vertigo. <span class="typehead">GI:</span> Nausea, vomiting, diarrhea, abdominal discomfort, indigestion, malaise. <span class="typehead">Hematologic:</span> (Rare) <span class="speceff-life">Agranulocytosis, aplastic anemia, bone marrow depression</span>, thrombocytopenia. <span class="typehead">Skin:</span> Urticaria or pruritus, pruritic maculopapular rash, toxic epidermal necrolysis. <span class="typehead">Other:</span>
<span class="speceff-life">Hepatotoxicity</span>, renal insufficiency. 
      <h1><a name="dtintefer">Diagnostic Test Interference</a></h1>
<p>Possibility of elevated blood levels of <span class="alt">alkaline phosphatase</span> and <span class="alt">serum transaminases (AST, ALT),</span> and decreased blood <span class="alt">Hct,</span>
<span class="alt">Hgb,</span>
<span class="alt">leukocytes.</span>
</p>
<h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span>
<b>Alcohol</b> may inhibit renal excretion of uric acid; <b>ampicillin,</b>
<b>amoxicillin</b> increase risk of skin rash; enhances anticoagulant effect of <b>warfarin;</b> toxicity from <b>azathioprine,</b>
<b>mercaptopurine,</b>
<b>cyclophosphamide,</b>
<b>cyclosporin</b> increased; increases hypoglycemic effects of <b>chlorpropamide</b>; <span class="classification">thiazides</span> increase risk of allopurinol toxicity and hypersensitivity (especially with impaired renal function); <span class="classification">ace inhibitors</span> increase risk of hypersensitivity; high dose vitamin C increases risk of kidney stone formation. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> 8090% absorbed from GI tract. <span class="typehead">Onset:</span> 2448 h. <span class="typehead">Peak:</span> 26 h. <span class="typehead">Metabolism:</span> 7580% metabolizes to the active metabolite oxypurinol. <span class="typehead">Elimination:</span> Slowly excreted in urine; excreted in breast milk. <span class="typehead">Half-Life:</span> 13 h; oxypurinol, 1830 h. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Monitor for therapeutic effectiveness which is indicated by normal serum and urinary uric acid levels usually by 13
            wk (aim of therapy is to lower serum uric acid level gradually to about 6 mg/dL), gradual decrease in size of tophi, absence
            of new tophaceous deposits (after approximately 6 mo), with consequent relief of joint pain and increased joint mobility.
         </li>
<li>Monitor for S&amp;S of an acute gouty attack which is most likely to occur during first 6 wk of therapy.</li>
<li>Lab tests: Monitor serum uric acid levels q12wk to check adequacy of dosage. Perform baseline CBC, liver and kidney
            function tests before therapy is initiated and then monthly, particularly during first few months. Check urinary pH at regular
            intervals.
         </li>
<li>Monitor patients with renal disorders more often; they tend to have a higher incidence of renal stones and drug toxicity problems.</li>
<li>Report onset of rash or fever immediately to physician; withdraw drug. Life-threatening toxicity syndrome can occur 24
            wk after initiation of therapy (more common with impaired renal function) and is generally accompanied by malaise, fever,
            and aching, a diffuse erythematous, desquamating rash, hepatic dysfunction, eosinophilia, and worsening of renal function.
         </li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Drink enough fluid to produce urinary output of at least 2000 mL/d (fluid intake of at least 3000 mL/d). (Note that 1000 mL
            is approximately equal to 1 quart.) Report diminishing urinary output, cloudy urine, unusual color or odor to urine, pain
            or discomfort on urination.
         </li>
<li>Report promptly the onset of itching or rash. Stop drug if a skin rash appears, even after 5 or more wk (and reportedly as
            long as 2 y) of therapy.
         </li>
<li>Minimize exposure of eyes to ultraviolet or sunlight which may stimulate the development of cataracts.</li>
<li>Do not drive or engage in potentially hazardous activities until response to drug is known.</li>
<li>Remain under medical supervision while taking allopurinol (generally continued indefinitely); drug can cause severe adverse
            reactions.
         </li>
<li>Do not breast feed while taking this drug without consulting physician.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>